Through this axis, NASH-inducing conditions such as MCDD or LPS treatment lead to inflammation and fibrosis by mobilizing the MLL4 complex to the hepatic inflammatory and M1 polarizing target genes of NF-κB-MLL4, which in turn facilitates their open chromatin formation. Here, NFKB1 is linked to metabolic dysfunction-associated steatohepatitis.